Podcasts about Leukemia

Caitlin White's son Grant was 2 years old when he complained of pain from his thumb in November of 2022. This pain was not taken seriously enough by his doctors, one of whom looked at Grant while he was lying on the floor and gasping for breath in the hospital waiting room and said that his "shift was almost over" and he would order him a prescription, which had been the supposed solution heard too many time before by Caitlin. Caitlin then demanded a change in doctors, receiving a new female doctor, and this led to Grant finally being diagnosed properly for Leukemia, and began his treatment almost immediately.

Happy Holidays, everyone!

What does it take to climb the tallest mountain in Africa — and why would someone take on that challenge in honor of a loved one?In this inspiring episode of Logistics With Purpose®, we sit down with Kieran Purtill to unpack his extraordinary journey to the summit of Mount Kilimanjaro, a climb driven by love, loss, and purpose. Kieran shares the deeply personal motivation behind the expedition — honoring his late mother — and how her legacy shaped every step of the journey.We dive into the physical, logistical, and emotional realities of preparing for and completing such a demanding climb, from months of training to the critical role of teamwork and support along the way. Kieran also reflects on the powerful lessons he learned about resilience, perseverance, mental strength, and community when facing adversity at altitude.Whether you're an adventurer, someone navigating loss, or simply looking for inspiration to pursue a meaningful goal, this conversation will challenge you to reflect on your own purpose — and remind you that courage and connection can carry you further than you ever imagined.Additional Links & Resources:Fundraiser Climbing Mt. Kilimanjaro for The Leukemia and Lymphoma Society and in Honor of Kathy Purtill - https://diy.bloodcancerunited.org/fundraiser/6467059Learn more about Logistics with Purpose®: https://supplychainnow.com/program/logistics-with-purposeLearn more about Vector Global Logistics: https://vectorgl.com/Subscribe to Logistics with Purpose®: https://logistics-with-purpose.captivate.fm/listenThis episode was hosted by Enrique Alvarez and Kristi Porter. For additional information, please visit our dedicated episode page at: https://supplychainnow.com/journey-purpose-epic-climb-kiliminjaro-leukemia-awareness-lwp145

In this week's episode, Blood editor Dr. Laurie Sehn interviews three of the latest Blood authors: Drs. Vijay Sankaran, Ruud Delwel, Françoise Kraeber-Bodere. Two studies on the MECOM gene have been paired in this episode, analyzing new groundwork for potential novel myeloid differentiation therapies via repression of MECOM restoring enhancer mediated CEBPA expression. We'll also hear about the results of CASSIOPET, imaging companion study of the CASSIOPEIA trial, and how achieving negativity in PET before starting maintenance therapy is significant even in patients who still show residual disease in the bone marrow.Featured ArticlesCEBPA repression by MECOM blocks differentiation to drive aggressive leukemiasMECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed from the CASSIOPEIA trial

In this episode, we speak with Synary Be, a resilient survivor of acute myeloid leukemia (AML), who shares her powerful journey of enduring three bone marrow transplants over eight years. Diagnosed suddenly in March 2017, Synary's story begins with a high fever that led to a shocking diagnosis: 93% leukemia. From that point on, her life transformed into a series of hospital stays, treatments, and moments that tested her strength and spirit.We learn how her first transplant involved two umbilical cord donors, one from the U.S. and another from Singapore. When that failed to graft, her younger brother flew from Australia to donate for her second transplant—a 50% match. After two years in remission, she relapsed again and required a third transplant, this time from her older brother, right in the midst of the COVID-19 pandemic. With travel restrictions in place, the donor cells had to be processed remotely and shipped to Stanford, showcasing the remarkable role of medical technology in saving lives.Despite being given only a 50% chance of survival for her third transplant, Synary put her trust in her doctors. Though she relapsed again, she now maintains remission through chemo pills. With no long-term data available for this new medication, she continues treatment cautiously and with optimism, trusting in the advancement of medicine.Synary spends some time opening up about the chronic graft-versus-host disease (GVHD) that followed her transplants. She explains its impact on her lungs, eyes, mouth, nails, and skin, detailing both the physical symptoms and the treatments that have helped her reclaim daily life. From scleral lenses to serum tears, to pulmonary rehab and steroid creams, she educates us on the challenges and management of GVHD.Beyond the physical toll, Synary discusses the mental health struggles tied to long-term illness—particularly anxiety from repeated hospitalizations. She emphasizes the importance of therapy, meditation, support groups, and the courage to seek help. Her words serve as a reminder that managing chronic illness includes caring for both mind and body.Synary's story wouldn't be complete without acknowledging her support system. Her husband, who acted as her full-time caregiver through 300 cumulative days of hospitalization, and her three children, endured major sacrifices. Friends and community support filled in the gaps, underscoring that no one should navigate transplant recovery alone.Even in the face of isolation, fatigue, and anxiety, Synary finds joy in simple pleasures: watching Christmas movies, going for walks, and spending time with family. Her message is clear—life is still good. And GVHD, while challenging, cannot take away her joy.Calm App — https://www.calm.comThanks to our Season 19 sponsors, Incyte and Sanofi.https://incyte.com/https://www.sanofi.com/en00:40 - Introduction to Synary Be01:20 - AML Diagnosis and First Transplant03:10 - Transplants and Donor Challenges04:06 - Relapses and Chemo Maintenance06:44 - Living with GVHD12:15 - GVHD Symptoms and Treatments13:40 - Support System and Caregiving15:34 - Isolation After Transplants16:38 - Mental Health & Anxiety19:03 - Coping and Finding Joy20:36 - Final Thoughts and Message of Hope National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Anthony and Bernie are joined by special guest, Dr. Justin Kaner from Weill Cornell Medicine, to discuss some of the most interesting ASH abstracts in leukemia in 2025! What abstracts should change practice? Listen to find out. Some of the abstracts discussed:PARADIGM: https://meetings-api.hematology.org/api/abstract/vmpreview/296881KMT2A Outcomes (MARROW Consortium and Othman, et al.): https://meetings-api.hematology.org/api/abstract/vmpreview/302582 and https://meetings-api.hematology.org/api/abstract/vmpreview/297333CLIA +/- Ven: https://meetings-api.hematology.org/api/abstract/vmpreview/302047FLT3i studies (and MRD): https://meetings-api.hematology.org/api/abstract/vmpreview/295719 and https://meetings-api.hematology.org/api/abstract/vmpreview/302699 and https://meetings-api.hematology.org/api/abstract/vmpreview/291322ALL GIMEMA Trial (blin + ponatinib): https://meetings-api.hematology.org/api/abstract/vmpreview/296532Menin inhibitor data

At the 2025 American Society of Hematology Annual Meeting & Exposition (ASH), CancerNetwork® sat down with a variety of researchers and clinicians to discuss potential advancements across hematologic oncology care. These experts shared their findings related to investigational therapeutic regimens and strategies that may prove impactful across different multiple myeloma, lymphoma, and leukemia populations. First, Krina K. Patel, MD, MSc, highlighted findings from the phase 2 iMMagine-1 study (NCT05396885) assessing treatment with anitocabtagene autoleucel (anito-cel) among patients with relapsed/refractory multiple myeloma. According to Patel, an associate professor in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, Texas, the novel cellular therapy elicited an overall response rate (ORR) of 96% and a stringent complete response or CR rate of 74% among the evaluable patients. She also discussed how anito-cel's unique mechanism of action may show efficiency compared with other cellular therapy products while reducing the risk of cytokine release syndrome and other delayed toxicities. Next, Manali Kamdar, MD, spoke about data from a long-term follow-up phase 2/3 study (NCT03435796) based on the phase 3 TRANSFORM trial (NCT03575351) evaluating lisocabtagene maraleucel (liso-cel; Breyanzi) vs standard-of-care therapy for patients with relapsed/refractory large B-cell lymphoma (LBCL). Long-term follow-up showed that liso-cel continued to elicit improvements in progression-free survival and overall survival across this population. Kamdar, the clinical director of Lymphoma Services at the University of Colorado Anschutz School of Medicine, touched upon the patient subpopulations who are most suitable to receive liso-cel while emphasizing the agent's curative potential in the second-line setting. Finally, Wei Ying Jen, BM BCh, MA, MMed, MRCP, FRCPath, detailed results from the phase 1/2 SAVE trial (NCT05360160), which showed responses with an all-oral combination of revumenib (Revuforj), decitabine/cedazuridine (Inqovi), and venetoclax (Venclexta) for patients with newly diagnosed acute myeloid leukemia. Jen, an assistant professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, Texas, noted how an all-oral regimen may offer an “advantage” compared with standard intensive chemotherapy, which requires patients to travel to the hospital to undergo an infusion. References Patel K, Dhakal B, Kaur G, et al. Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: updated results from iMMagine-1. Blood. 2025;146(suppl 1):256. doi:10.1182/blood-2025-256 Kamdar M, Solomon S, Arnason J, et al. Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM. Blood. 2025;146(suppl 1):3710. doi.10.1182/blood-2025-3710 Jen WY, DiNardo CD, Short NJ, et al. Phase II study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML. Blood. 2025;146(suppl 1):47. doi:10.1182/blood-2025-47

To have Dr. Morse answer a question, visit: https://drmorses.tv/ask/   Dr. Morse Q&A - Tumor - Leukemia - Vitamin C - Prostate Cancer and More #815 00:00:00 - Intro 00:00:28 - Tumor - Leukemia - Liposomal Vitamin C  00:07:40 - Stage 4 Prostate Cancer 00:00:28 - Tumor - Leukemia - Liposomal Vitamin C  Is there any circumstance where Dr Morse would recommend using Liposomal Vitamin C? 00:07:40 - Stage 4 Prostate Cancer I would like your help please, I want to know if I guided my nephew correctly.

Ladies and gentlemen, welcome back to The Real Takk Podcast, where we dive deep into the high-stakes world of NYC real estate, the stories behind the deals, and the lives of the power players making it all happen.  AND it's that time of the year again!  The end-of-the-year wrap-up pod is here, where we discuss all things real estate in 2025, along with our prediction pod for real estate in 2026! Today, I'm absolutely thrilled to introduce our guest, Esther Patten, a powerhouse real estate agent with Compass in the heart of NYC. With over 15 years of expertise navigating the fast-paced worlds of Manhattan and Brooklyn, Esther is your go-to expert for everything from sleek condo sales and co-op closings to savvy multi-family investments, cutting-edge new developments, and seamless residential leasing. She's shattered records—like setting the bar for the priciest townhouse in Bedford-Stuyvesant at 1 Verona Place—and has racked up an impressive $360 million in transactions, all while building her success almost entirely on glowing client referrals and deep-rooted connections with investors, developers, buyers, and sellers across the city. A proud Northwestern University alum and former Division I women's basketball player, Esther brings that same competitive edge and Midwestern grit to every deal, making her an invaluable resource for clients from Chicago and beyond. She's passionate about giving back, supporting causes like the Leukemia and Lymphoma Society and Meals on Wheels NYC, and when she's not outpacing the market, you'll find her dominating on the court in women's basketball leagues or fueling up with high-energy workouts at Barry's Bootcamp and Tone House. @estherpatten

In this deeply personal and long-awaited episode, we offer an update on our lives since our last regular PAWsitive Choices content. We share our journey navigating two profound family challenges that began almost simultaneously last year: my mother-in-law, Julie, was diagnosed with stage 4 pancreatic cancer, and just three months later, my husband and co-host, Thomas, was diagnosed with leukemia. Julie embraced her role as our "Cancer Club President," walking alongside us in solidarity until her passing in September.We realized that the resilience, growth mindset, and brain-based strategies we taught through PAWsitive Choices became our absolute lifeline. This immediate need for coping tools led us to launch our new show, The Brain It On! Podcast, where we continue to share these strategies through cancer treatment and beyond. To give you the full story, we are sharing the first episode of The Brain it On! Podcast, recorded live from Thomas's hospital room. At the time of this original recording, Thomas' mother was still with us. Julie has since passed away from pancreatic cancer. This episode captures the beginning of our journeys through cancer. 

Dr. Alison Loren and Dr. Ann Partridge share the latest guideline from ASCO on the management of cancer during pregnancy. They highlight the importance of this multidisciplinary, evidence-based guideline and overarching principles for the management of cancer during pregnancy. Drs. Loren and Partridge discuss key recommendations from each section of the guideline, including diagnostic evaluation, oncologic management, obstetrical management, and psychological and social support. They also touch on the importance of this guideline and accompanying tools for clinicians and how this serves as a framework for pregnant patients with cancer. The conversation wraps up with a discussion on the unanswered questions and how future evidence will inform guideline updates.  Read the full guideline, "Management of Cancer During Pregnancy: ASCO Guideline" at www.asco.org/survivorship-guidelines TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/survivorship-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-02115   Brittany Harvey: Hello and welcome to the ASCO Guidelines Podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I am interviewing Dr. Alison Loren from the Perelman School of Medicine of the University of Pennsylvania and Dr. Ann Partridge from Dana-Farber Cancer Institute, co-chairs on "Management of Cancer During Pregnancy: ASCO Guideline." Thank you for being here today, Dr. Loren and Dr. Partridge. Dr. Alison Loren: Thanks for having us. Dr. Ann Partridge: It's a pleasure. Brittany Harvey: And then just before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Partridge and Dr. Loren who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then to dive into the meat of this guideline, to start us off, Dr. Loren, could you provide an overview of the scope and purpose of this new guideline on the optimal management of cancer during pregnancy? Dr. Alison Loren: Sure, thanks, Brittany. So this was really born out of I think a lot of passion and concern for this really vulnerable patient population. We have observed, and I am sure it is not any surprise to your audience, that the incidence of cancer in young people is increasing. And simultaneously, people are choosing to become pregnant at older ages, and so we are seeing more and more people with a cancer diagnosis during their pregnancy. And for probably obvious reasons, there is really no way to do randomized clinical trials in this population. And so really trying to assemble and articulate the best evidence for safely managing the diagnosis of cancer, the management of cancer once it is confirmed, being thoughtful about obviously the health of the mom, but also attending to potential risks to the developing fetus, and really just trying to be really comprehensive and balanced about all the choices for these patients when they are facing some really challenging decisions in a very emotionally fraught environment. And I think it is really emotionally fraught for the providers, too. You know, this is obviously an extremely intense, very emotional set of decisions, and so trying to provide a rudder essentially to sort of help people frame the questions and trying to make as evidence-based a set of recommendations as possible. Dr. Ann Partridge: And I would just add that "evidence-based" is a strong word here because typically our, as you just heard, our gold standard evidence is a randomized trial, but you can't do that in this setting, in general. And so, what we were able to do with the support of the phenomenal ASCO staff was to pull together kind of the world's literature on the safety and outcomes of treatments during pregnancy, as well as consensus opinion. And I think that is a really, really critical difference about this particular guideline compared to many of the other ones that ASCO does, where consensus and good judgment needed to kind of rule the day when evidence is not available. So, there is a lot of that in our recommendations. Dr. Alison Loren: That is such a good point. And I just, before we move forward, I just want to reflect that the composition of the panel was really broad and wide-ranging. We had maternal medicine specialists, we had legal and ethical experts, we had representatives who understand pharmaceutical industries' perspectives, and then medical oncologists representing the full spectrum of oncology diagnoses. And so it was a really diverse, in terms of expertise, panel, internationally composed to try to really get the best consensus that we could in the absence of gold standard evidence. Brittany Harvey: Absolutely. That multidisciplinary panel is really key to developing this guideline and, as you said, looking at the evidence and even though it does not reach the level of randomized trials, still critically evaluating it and reviewing that along with consensus to come up with optimal management for diagnosis and management of cancer during pregnancy. So then to follow that up, I would like to next review the key recommendations of the guideline across the main sections that the expert panel provided. First, I will throw this out to either of you, but what are the important general principles for the management of cancer during pregnancy? Dr. Ann Partridge: I think there were three major principles that we hammer home in the guidelines. One is that this is a team sport. It is multidisciplinary care that is necessary in order to optimize outcomes for the patient and potentially for the fetus. And that you really need to, from the beginning, bring in a coordinated team, including not just oncologists but obstetricians, maternal-fetal medicine specialists, neonatologists, ethics consultants, and obviously the patient and potentially her family. So that, I think, is one of the most important things. Second would be that obviously in a pregnancy, there are two potential patients and that the nuances of safety and risk from treatment is really wrapped up in where in the trimester of the pregnancy the patient is diagnosed, along with the kind of cancer that it is, both the urgency of treatment and the risk of the cancer, as well as the potential risks of any given intervention across the cancer continuum. It is a broad guideline in that regard. And then finally, and this is particularly timely given what is going on from a sociopolitical standpoint in the U.S., really thinking about informed consent and potential ethical as well as legal implications of some of the choices that patients might have when they are thinking about, in particular, continuing a pregnancy or potential termination. Dr. Alison Loren: And I will just add that I think that the key to all of this guidance is nuance and individualization and also making sure that patients and their care providers understand all the choices that are available to them and also the consequences of those choices. You know, nobody would choose to receive chemotherapy during pregnancy if that wasn't necessary. So there are risks to treatment, but there are also risks to not treatment. And making sure that in a suboptimal situation where you do not have a lot of evidence, trying to weigh, the best you can, the risks and benefits of all of the choices so that the patient can come to a decision about the treatment plan that is right for her. Brittany Harvey: Definitely. And those core concepts really set the stage for individualized care on what is necessary for appropriate multidisciplinary care, prioritizing both patient autonomy and informed decision making. With those core concepts and key principles in mind, I would like to move into the recommendations section of the guideline. So what are the key recommendations regarding diagnostic evaluation for pregnant patients with signs or symptoms of cancer? Dr. Alison Loren: I think the most important thing is to not delay, that there are very careful and well-thought-out recommendations for how to evaluate a potential cancer. And while there are certain things that we know can be harmful, particularly when certain dose thresholds are exceeded - for instance, abdominal imaging, there are certain radiographic thresholds that you don't want to exceed because of risk of harm to the embryo or fetus - there are still lots of options for diagnosing cancer during pregnancy. And again, thinking about the costs of not doing versus the cost of doing, right? It is really important to make the diagnosis of cancer if that is a consideration or a concern. And sometimes going directly to biopsies or getting definitive studies, even if there is a small risk to the developing fetus, is really essential because if the mom does not survive, of course, the fetus is also not going to survive. And so we need to be thinking first about the patient who is sitting in front of us, the woman who needs to know what is going on in her body so she can make good decisions about her health. So, I think that is a key principle in thinking about this. Brittany Harvey: Absolutely. So, following that diagnosis of a new or recurrent cancer, what is recommended for oncologic management of patients who are diagnosed with cancer during their pregnancy? Dr. Ann Partridge: So, I think the general principle is, again, cancer is such a wide number of diseases and even within diseases, a range of stages and risks and associated opportunities for risk reduction and/or treatment depending on the type of cancer. Just by example, in the work that I do, which is breast cancer, once someone has had a surgery in the early-stage setting, a lot of our treatment is about risk reduction. And that is very different than from what Alison does, which is treating people with leukemia, where it is kind of binary. If you do not treat, including with cytotoxic drugs, the patient and an unborn fetus will die, especially early in the pregnancy, obviously. So this is where cancers are very, very different. So I think taking the approach of what would you do if the patient were not pregnant? And what is the best treatment for that particular patient with that particular kind of cancer? And then applying the pregnancy and where the patient is in that pregnancy in terms of the trimester of the pregnancy, and what is safe and what is unsafe from the options that you would give her if she were not pregnant. And then if the patient is choosing to keep the pregnancy, which in my practice, many people come and they come to me because they want to hold onto their pregnancy and want to figure out how to make it work, coming up with a regimen that tries to give them kind of the best bang for the buck, the best possible breast cancer therapy with the least harm, when possible, to the fetus. It is a bit of a balance, right? And then we cannot always give people the best approach. And sometimes it comes down to making a decision to give up something that may improve their survival so as not to harm the fetus. And sometimes it goes the opposite direction where a patient will say, "Oh, that is going to improve my survival by 5% and you can't give it to me now? I am going to choose to terminate." Even though that is obviously a very, very difficult and challenging decision to make in this setting because they want to optimize their survival and ideally live on to potentially have another pregnancy in the future if that is something that is of interest to her. So these are really, really hard conversations as you can imagine, but that is kind of where we go. Dr. Alison Loren: Yeah, and I think this is where the need for more research and understanding is really key because sometimes questions come up. I guess I am thinking about like HER2-directed agents, which we know are contraindicated in pregnancy. But what about sequencing? Does it matter when you get it? Can you get it later? I think that is something that we don't really fully understand. And similarly, again, this is obviously like a breast cancer and blood cancer focused discussion because that is what we do, but thinking about managing blood cancers, certainly with acute lymphoblastic leukemia, there is actually a lot of options now that, you know, you could potentially use to temporize or sort of get somebody through a pregnancy relatively safely. I am focusing on the word "relatively" because we do not know what the long-term impact might be of potentially not optimal therapy in the long run. And then thinking about other things like timing of a bone marrow transplant relative to either delivery or termination. I mean, again, we really do not know what are the right sets of sort of timing considerations for those. So there are just a lot of unknowns. And I think trying to be sort of self-aware and humble and honest about those unknowns so that the patient can engage in the conversation in a way that is meaningful to her and make the decisions that make the most sense for her. I think the most important thing is to make sure that the patient feels supported and safe to make those decisions with as little regret as possible. Brittany Harvey: Yes, I think it is really important that you mentioned that there is a wide range of cancers here, and that means that care really needs to be individualized for each patient. I will also note, just in this section, that I found really informative while reading through the guideline the list of oncologic agents that may be offered in each individual trimester, whether it is contraindicated or it can be used with caution, or if there is relatively good safety data on it for prioritizing maternal treatment needs and balancing fetal safety at the same time. I think that is, that is really key. And I think readers will really like that section of the guideline to provide concrete information for them and their patients. Dr. Alison Loren: Thank you. We actually spent a lot of time on that table and just thinking about what it should look like, what the format ought to be, what the language ought to be. Because of course, at the end of the day, everything should be used with caution. So what does that actually mean? And we sort of tried to explicate that a little bit in like the footnotes. We really tried to leverage what we know from clinical experience, from package labels, from mechanism of action to try to be as clear and definitive as we could be without overstating or understating what we know. Dr. Ann Partridge: Yeah, and I think we are focusing on breast and leukemia because that is what we do. But the truth is much of the data comes from those two areas. Leukemia, not because it is so common, but because you do not really have choices to treat or not treat. And so for decades, they have been treating and saying, "We hope the progeny comes out okay." And for many agents it does. The babies are okay. And so, we have reasonable observational data. And then in breast cancer, there have been actually some prospective registry-type studies where people have been followed and treated when pregnant, and the progeny have been accounted for, and so we have some good experience in that way too. Again, not randomized trials, but at least data that suggests certain agents are safe. And increasingly, because of that, when we have had to treat patients, we have said, "Okay, let us do it on this registry so that we can at least learn from every patient that comes in in this situation." And so, I think we will have more and more data given the growing number of young adults with cancer and the delays in childbearing that are happening around the world, and particularly in Westernized countries. I wish we did not. We wish we did not see this problem, but of course, when we do, we have to make sure that we learn from it and try and get patients enrolled in these registries and any kinds of studies that are available. Dr. Alison Loren: Yeah, I will just underscore that to say that, you know, there is outcomes of pregnancy and then there is outcomes of pregnancy, right? So there is like, "Okay, the baby was born with 10 fingers and 10 toes, and they passed their Apgar, and they are doing all their developmental processes along the way." But what happens when they are 10 or 15 or 20? Are they maturing normally? Are they cognitively intact? And then, of course, it is really inseparable from what is the impact on a family of having the mom with cancer? And how does that impact childhood development and intellectual development? And so these are really, really important questions that are very difficult to answer given the longitudinal information that you need, but it is a really critical question that, you know, patients ask and we do not know the answer. Dr. Ann Partridge: Yeah, that actually leads me to one of the important principles in the guideline that is a little bit of a change from when I first started practicing, which is we have learned from the wider neonatology literature, as they have followed up on the children that were born prematurely, that it is actually better not to be premature and to keep the baby in utero as long as it is safe for the fetus and the mother as long as possible, ideally to term rather than delivering early and then giving the chemo after that or separating the chemo from before and after. We used to try and deliver early and then give agents, but now we typically will give agents that are safe to be given at the end of pregnancy, ideally close to term, a couple weeks out, to allow for the ability of count recovery, and you do not want to go into preterm labor with chemotherapy on board, but we used to go much earlier and have an argument with our maternal-fetal medicine doctors. "How early can you get them out?" And they would say, "How long can they stay in?" And increasingly, we have been able to try and compromise to go even later and allow the fetus to go to term because of the neonatal outcomes that in longer term there is a suggestion that the children are developing better in the long run if they are kept in utero for as long as possible. Dr. Alison Loren: Yeah, that is such a great point. I think that is probably the most important thing for people to take away. For anyone who sort of does this, I mean, no one does this regularly because it is a rare event, although I think it is increasing as I mentioned. But this idea that the third trimester is, most of us know, is primarily a time for growth. Most of the critical development has already occurred, and so administering most chemotherapy agents towards the end of the third trimester seems to be preferable long term than delivering them early. So that is a really big change. I think we used to try to sort of, "Oh, get them to 30 or 32 weeks and then deliver," but we really are trying to get them closer to term, 37 weeks or more, and then coordinating the treatment so that they are not nadiring, as Ann said, at the time of planned delivery. Brittany Harvey: Yes, and that is a really important point related to evidence-based care and why we have changed that practice. And so then that actually leads nicely into my next question. But as you both mentioned, this is an important collaboration between oncologists and obstetricians. So the next section of the guideline addresses obstetrical practice. And so beyond what is standard, what additional recommendations are there in obstetrical management for pregnant patients with cancer? Dr. Alison Loren: That is a great question. So I will say we were really struggling with like how much do we cover? Like this is an oncology guideline. We are not obstetricians. We certainly had great representation from our maternal-fetal medicine colleagues on the panel. But really trying to sort of give useful information without overstepping. And so I think that the main recommendations are to increase the frequency of fetal monitoring, make sure that there is close attention to blood counts in the patient. But I think there is really still a gap in terms of what we know about optimal management of a pregnant person who is receiving therapy and how to handle the pregnancy itself. The delivery should be a usual delivery. Our colleagues did not recommend a planned C-section. They recommended usual care in terms of planning for the delivery. Obviously, if a C-section is indicated, then it should be done, but it should not be planned this way because of the cancer diagnosis. And I guess the other thing that we mentioned in the guideline, although we were reluctant to push it too hard because of access to these specialized services, was evaluating the placenta after birth to ensure that there were no metastases in the placenta itself. Dr. Ann Partridge: Those are the main things, and judicious and prudent obstetrical care, as I think, you know, is trying to be practiced regularly with MFM. Typically these patients should be followed not by your average OB/GYN, but a maternal-fetal medicine specialist because these patients will have special concerns, especially if they are sick. So oftentimes, especially Alison's patients, are actually sick with leukemia. And so you are monitoring them a lot, whereas, you know, a breast cancer patient typically isn't sick, although they could get sick with their chemotherapy. And so we really want to hand-in-hand manage these patients with our MFM colleagues. Dr. Alison Loren: I think we also highlighted in the guideline just for the refresher purposes of the oncology community, generally which drugs that would be given in a normal oncology setting are safe to be given to a pregnant person. So we talked a little bit about what kinds of steroids are recommended, antiemetics, DVT prophylaxis, peripartum. These are things that we think about a lot in oncology, but just want to make sure that it sort of intersected appropriately with the care of a pregnant patient. Brittany Harvey: Definitely. That specialized care is really important for patients who are pregnant and have cancer. And then the last section of the recommendations addresses psychological and social support. As you both mentioned before, this is a highly emotional time and it can be difficult and challenging to make decisions. So what is recommended for the psychological and social support of pregnant patients with cancer? Dr. Ann Partridge: Well, as I said, it is really something that needs to be considered at the beginning, through the diagnostic period, all the way into survivorship. Ironically, even though it is a highly fraught, emotional situation, I find that my pregnant patients actually are extraordinarily resilient, and what they are really focused on often is the safety of the fetus, because again, many of the people that come to me, it is a highly wanted pregnancy. They are also focused on their own health, of course, and often you need to bring in social work, sometimes a psychologist, professionals who are there just to help manage their emotions while we are focusing on what do they need medically to be as healthy as possible, both for the again, the mother, the patient, and the fetus. It is very tricky, and I will say also bringing in sometimes people on the ethics team in the hospital to help, both from the "Are you recommending and giving something that is safe?" That is number one. And then number two, sometimes patients want to be treated with drugs that we do not have any safety data for in pregnancy. What are our obligations? I think most of us would say we would not treat someone if we do not have safety data and there is suspicion for concern. But where is that line in terms of the right thing to do by that patient? And so we are all beholden to our ethics colleagues to help us when we make decisions like that. You know, we all want to do right by the patient, but we have to uphold our oaths and legal obligations. I don't know if you have to add on that because it's very tricky. Dr. Alison Loren: It is, it is very hard. I mean, I think, you know, there is a lot of emotion, obviously any cancer diagnosis is extremely charged and people are already at sort of a heightened, you know, they are anticipating a new baby and planning around that. And so it is just an extremely disruptive is the smallest word I can think of to describe it. And I think that often there is a co-parent, there might be parents and in-laws and other siblings, and then there is care after delivery. And so it is just a very complex set of dynamics. And having both our ethics colleagues and our psychology and social work colleagues to sort of just pitch in and make sure that the patient is being supported. I think there are sometimes really difficult situations where maybe what the patient wants is different from what the father of the baby wants or what the rest of the family wants. And so that can be really challenging. And you never really know where those landmines are going to pop up. So it is good to have the team on board early and often. Dr. Ann Partridge: Yeah, I would add to that, the other thing here that I think is really important, like in all of medicine but especially in situations like this, this is where we have to be very careful as professionals not to impose our own ethical, moral, emotional, personal views on the patient and to try to reserve judgment as much as possible. We are their navigator with the most important evidence and information that we can provide in the current situation. And that is where this guideline is extraordinarily helpful, we hope, for clinicians in the years to come. And at the same time, we cannot necessarily impose our own views and what we would do on a patient or what we tell our daughters, sisters, friends, family members. It is very tricky in that way. And so sometimes not just support for the patient, but support for the care team may be warranted in some of these very fraught situations. Dr. Alison Loren: Yeah, that is such a great point. And I was sort of thinking that too. I mean, it is, of course, the patient is front and center, but these are really difficult situations to navigate. And I will just add also that a lot of times these patients end up in academic centers, which I think is that's where the expertise or even just the experience may be. But the downside of that is that, you know, the teams are constantly changing. You have a new resident, you have a new intern, you have a new attending, a new fellow. And so, you know, the patients may be subjected to lots of different ways of communicating and sometimes those perceived differences can be really challenging. So sort of team huddles to sort of make sure that everybody is reading from the same script and everyone is comfortable with how the information is being presented so that the patient does not feel more confused or more overwhelmed, that they are kind of getting a consistent message from the whole team that, "This is what we know, this is what we are recommending, here are your other choices, and here are the pros and cons of each of these options." Brittany Harvey: Yes, I think you have both touched on this and that bringing in appropriate experts to support both clinicians and patients and their decision-making and their mental health is really important for this section of the guideline. We have already discussed this a fair bit throughout our conversation, but in your view, what is the importance of this guideline and how will it impact both clinicians and pregnant patients diagnosed with cancer? Dr. Ann Partridge: I could start with that. We just talked about experts and having them all around, but the fact is most people do not have the experts all around when they are dealing with this. And I think this is, you know, an expert-based, evidence-based guideline where having this in one's back pocket, whether you are in rural Montana or at a major cancer center on either coast, you will be armed with the latest and the greatest in terms of what we know and what we do not know, and some very helpful algorithms for how to think through the process of dealing with a patient who is diagnosed during pregnancy, whichever type of cancer it is. We could not cover every single specific thing about every cancer, although it is a pretty long guideline and there is a lot of nuance in there. So you might find a lot about specific cancers. And I think that that will be very, very helpful for people who are faced with this situation in the clinics just to frame it out, think through. Sometimes there is no answer that is the perfect answer and then, you know, using this as kind of a scaffolding and phoning a friend who may have more experience to help guide you and guide the patient, most importantly. I think it will be very helpful in that regard. Dr. Alison Loren: Yeah, I think so too. And I have talked about that we are working on this guideline and the anecdotal feedback has been, "This is so helpful." Like there really has not been, I think, an all-in-one place, diagnostic considerations, radiographic considerations, staging, treatment, all the modalities, surgical, radiation, systemic chemotherapy. We tried to include, when we could, novel agents including targeted agents and monoclonal antibodies and bispecifics and cellular immunotherapies and non-cellular immunotherapies. We really, really tried to cover in 2025 what are people using to treat cancer and to try to give the most balanced view of what we think is is safe or reasonably safe and what we think is either unproven or known to be risky, really to have it be kind of a go-to, like all-in-one, as much information as we have about these really challenging cases. We tried to include, Ann mentioned, you know, specific cancers, and I think when there were specific things to shout out with specific cancers, we really tried to highlight that. Like, "Okay, lots of young patients with cancer have Hodgkin's lymphoma, so what is safe and what is not for that specific case?" Or, "What is safe or what is not when you are thinking about colon cancers?" And we have a shout-out in here about considering checking for DPD deficiencies in patients who are pregnant. And I know it is generally recommended nowadays, but certainly for people who are pregnant, you know, you really want to avoid excess toxicity. So I think just really trying to be attentive to specifics about certain cancers in young patients and what would be valuable for a practicing oncologist and obstetrician to know when you are faced with this situation. Dr. Ann Partridge: Yeah, and I think the other critical thing that is great about this guideline is it's a starting place. And I anticipate that we will be building on this guideline for many years to come. And remember that when first, I was not around then, but probably three or four decades ago, when chemotherapy was just coming out and patients were coming in pregnant, there was a feeling I am sure that was, "We cannot give this to this person because it is purposefully going to destroy cells. And when you destroy cells in a growing fetus, you are going to destroy or harm that fetus." And yet, people did not have great choices. It was get treated or die, especially with things like leukemia early on. And bold patients along with their oncologist said, "Bring it on." And that is how some of this literature has been born. And so moving forward, there will be either purposeful exposures or inadvertent exposures of some of our therapies where we will learn ultimately. And this is a place where we can update these guidelines. That is the beautiful thing about the ASCO guidelines is that they are constantly being thought about to be updated. And then when there is enough of a change in practice, they will be updated such that they will continue to inform how we do this in the years to come for patients who come in pregnant. Dr. Allison Loren: Yeah, and I will say I have been doing this long enough now, we were just talking about a different guideline, the fertility guideline earlier today, and over the 20 years that the fertility guidelines have been out, just the amount of research has really skyrocketed. And you can see as you look at each guideline how much we have learned, what we can say, "Yes, this is working," "No, this is not working." Like, it is stuff that we used to say, "Oh, we do not really know," and now we have answers.  I think I speak for both of us when I say that we are hopeful that this will serve as, as Ann said, as a starting off point and really inspire people to ask the questions and do the research so that we can give better guidance moving forward, really trying to think about, you know, mechanisms and leaning on our colleagues in pharma and in the government who sort of think about safety and efficacy, to sort of make sure that they are contemplating not just non-pregnant patients, but also pregnant patients or as they are thinking about marking the package inserts with safety guidelines around this. Brittany Harvey: Yes, this is a critically important first guideline on the management of cancer during pregnancy, and we will look forward to continuing to build on that. I think as you mentioned, this guideline is far-reaching and has a lot of recommendations in it. And so both the full text of the guideline and those at-a-glance algorithms, figures, and tables will be really useful for clinicians in their clinic. Finally, to wrap us up, we have just been discussing this a little bit, but specifically, what are the outstanding questions on the management of pregnant patients with cancer, and where is this further research needed? Dr. Alison Loren: There are lots and lots and lots of unanswered questions. And I think if you look at the table, most of what we say is, "We are pretty sure this is okay, we are not so sure about this." I am paraphrasing, but we really just are operating in a paucity of what we would normally consider gold-standard evidence. It is hard to imagine, of course, there would ever be, as we mentioned in the beginning, randomized trials. But I think that preclinical data, mechanistic data, trying to think about including as we go through animal data, making sure that we are looking at female animals and pregnant animals so that we can sort of fully understand what the impact may be. And then I think thinking about more localized therapies around sort of radiation, you know, we are now moving into really hyper-focused radiation treatments like protons. Is that better because there is less scatter? Like I think those are real considerations that we just do not know the answer to. What do you think? Dr. Ann Partridge: I think so many unanswered questions, and this is a call to action to continue to and increase the documentation of the experiences and outcomes for patients diagnosed during pregnancy. Dr. Alison Loren: Yeah, and I think the long-term outcomes too are really going to be critical. Brittany Harvey: Yes, we will look forward to learning about more evidence across the spectrum of care to inform future updates to this guideline. So I want to thank you both so much for your work to develop this guideline, to review the extensive amounts of literature that you did, and work to create this guideline. And thank you also for your time today, Dr. Loren and Dr. Partridge. Dr. Alison Loren: Thanks. It was fun. Dr. Ann Partridge: Yeah, thank you. Brittany Harvey: And finally, thank you to all of our listeners for tuning into the ASCO Guidelines Podcast. To read the full guideline, go to www.asco.org/survivorship-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. 

In this Review Series episode, Blood Associate Editor, Dr. Elisabeth Battinelli discusses the Platelet Heterogeneity with authors Drs. Craig Morrell, Larry Frelinger, and Leo Nicolai.  Find the full review series in volume 146 issue 24 of Blood. 

Brad Ferland hold a tribute to Jon Gailmor, renowned Vermont musician, died peacefully on November 30, 2025 after a year and a half long battle with Leukemia. He died with his family surrounding him, at his son's home, with his music playing and his family singing along. Featuring Jack Donovan in the studio, Patti Casey, Elisabeth Von Trapp and Taryn Noelle. Also, Elliott Greenblott with AARP Fraud watch. Finally. Rob Smolla. Former President of Vermont Law and Graduate School on rules and constitutional law on the second strike on the suspected drug boat and other constitutional challenges and separation of powers. Rodney Smolla assumed the position of president of Vermont Law and Graduate School on July 1, 2022. After three years of dedicated service, he stepped down from his role as president, effective July 1, 2025, to focus on writing and teaching as a member of the VLGS faculty.This episode of Vermont Viewpoint was published 12/08/2025.

In this special episode, Blood editor Dr. Laura Michaelis interviews Dr. Arielle Langer and Blood Associate editor Dr. Marc Blondon for this special Maternal Health episode. In honor of the second Maternal Health compendium, both discuss their papers featured in this special collection. Featured Articles: β-Thalassemia minor is associated with high rates of worsening anemia in pregnancyLongitudinal profile of estrogen-related thrombotic biomarkers after cessation of combined hormonal contraceptivesSee the entire Maternal Health Compendium Second Edition

 In this week's episode, Blood editor Dr. James Griffin speaks with Drs. Emanuele Zucca and Sandra Pinho about their latest articles published in Blood. Dr. Zucca discusses his second analysis of the IELSG37 trial, where findings suggested that R-CHOP21 rituximab, cyclophosphamide,doxorubicin, vincristine, and prednisone, administered every 21 days) may be a suboptimal frontline regimen for PMBCL. Dr. Pinho discusses the aging megakaryocytic niche and its influence on the age-associated decline in HSC and progenitor cell function. The authors demonstrate that remodeling of the megakaryocytic niche and associated platelet factor 4 (PF4) downregulation are central mechanisms driving HSC aging.Featured Articles: Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial Platelet Factor 4 (PF4) Regulates Hematopoietic Stem Cell Aging 

Dr. Ian Fairlie speaking at Dr. Helen Caldicott’s Symposium: Fukushima Two Years Later: NYC – March 11-12, 2013 This Week’s Featured Interview: Dr. Ian Fairlie, UK-based radiation expert, compiled statistics from 60 international studies done on leukemia rates for children living within 5 kilometers/3 miles of a nuclear reactor. His shocking results – all supported...

Useless Talent Jason Mamoa AND vibrators? Sounds like a good night to me.  Our fan favorite is Samantha! She wants to shout out The Leukemia and Lymphoma Society in memory of her sister.    Please remember to Rate, Review, and Subscribe on Apple Podcast and Spotify.  If you would like to write in, find us on Patreon, buy MERCH, or find our social handles, go to our website,⁠ www.myskepticalsister.com You can also support us with a one time donation at https://www.buymeacoffee.com/myskepticaz

In this week's episode, Blood editor Dr. Laurie Sehn interviews authors Drs. Lorenzo Falchi and Robert Levy on their latest papers published in Blood Journal. Dr. Falchi discusses his work on an open-label, multicenter phase 1b/2 study evaluating fixed-duration epcoritamab with rituximab and lenalidomide in 108 patients with relapsed or refractory follicular lymphoma. Dr. Levy shares his work on demonstrating that in vivo expansion of Tregs in recipients prior to transplant is possible by activating TNFRSF25 (also known as death receptor 3) in combination with low-dose interleukin-2 in preclinical models. Both papers showed impressive and promising results for the treatment of lymphoma and GVHD.Featured ArticlesFixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular LymphomaPre-transplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues ameliorating GVHD post-HSCT

In this week's episode, Blood editor Dr. Laura Michaelis interviews authors Drs. Terri Parker and Peter Lenting on their latest papers published in Blood Journal. Dr. Lenting discusses his work on introducing a new therapeutic approach to von Willebrand disease with the development of a novel bispecific antibody (KB-V13A12) that links endogenous mouse VWF to albumin, extending VWF half-life twofold with cessation of provoked bleeding. Dr Parker shares the results of a 43-patient phase 2 study that evaluates the single agent isatuximab, a CD38 monoclonal antibody, in patients with relapsed/refractory AL amyloidosis. With a hematological response rate of 77%, organ response rates between 50 and 57%, and an excellent safety profile, the current study lays the foundation for future use of isatuximab across treatment settings and combination strategies.Featured ArticlesIsatuximab for Relapsed and/or Refractory AL Amyloidosis: Results of a Prospective Phase 2 Trial (SWOG S1702)A bispecific nanobody for the treatment of von Willebrand disease type 1

Paul J. Hampel, MD, Mayo Clinic, Rochester, MN Recorded on November 4, 2025 Paul J. Hampel, MD Assistant Professor of Medicine Division of Hematology, Department of Medicine Mayo Clinic Rochester, MN In this episode, Dr. Paul Hampel from Mayo Clinic Rochester takes a comprehensive look at hairy cell leukemia (HCL). He reviews the current diagnostic work-up, including immunophenotypic and molecular testing, and highlights key clinical features that distinguish HCL from related disorders. Dr. Hampel also discusses approved frontline therapies and evidence-based approaches for relapsed or refractory disease, with attention to infection risk and supportive care. The conversation explores emerging agents, novel combinations, and clinical trials shaping the next wave of HCL management. Join us for this expert discussion, offering practical insights to enhance care and outcomes for patients with HCL.

What happens when a 56-year-old woman who's never lifted weights walks into a gym and decides to compete in bodybuilding, and then were diagnosed with leukemia at 57? Most people would scale back, play it safe, maybe give up entirely. But Helen Fritsch did the opposite – she doubled down on building muscle. Helen never entered a weight room until her late 50s - she thought it was "for boys only." As a flight attendant and certified wine specialist, she spent decades doing cardio and avoiding heavy weights. At 56, she gave herself one month to prep for her first competition (most people take 12-16 weeks!) Two weeks in, her body transformation was so dramatic she couldn't believe it. She placed third. By 60, she'd won her pro card. Then at 57, a routine blood test revealed she had leukemia.  Instead of watching and waiting as her oncologist suggested, Helen discovered research showing cancer patients with more muscle mass have significantly better survival rates. She dove into hormone optimization (learning most women get inadequate doses), peptide therapy, and serious weight training. Today at 68, she's stronger than she was at 30 and convinced that building muscle saved her life. This isn't just another fitness story - it's proof that everything you've been told about aging, muscle building after menopause, and "taking it easy" after 50 is wrong.   Learn More About Helen Fritsch   Instagram ➜ https://www.instagram.com/helenfritsch_ifbbpro  Website ➜  https://www.ageisirrelevant.com/   Thank you to our show sponsors! TIMELINE: Timeline is offering 20% off your order of Mitopure! Go to https://timeline.com/NATALIEJILL  Free Gifts for being a listener of Midlife Conversations! Mastering the Midlife Midsection Guide: https://theflatbellyguide.com/ Age Optimizing and Supplement Guide: https://ageoptimizer.com   Connect with me on social media! Instagram: www.Instagram.com/Nataliejllfit Facebook: www.Facebook.com/Nataliejillfit   For advertising inquiries: https://www.category3.ca/  Disclaimer: Information provided in the Midlife Conversations podcast is for informational purposes only. This information is NOT intended as a substitute for the advice provided by your physician or other healthcare professional. Do not use the information provided in this podcast for diagnosing or treating a health problem or disease, or prescribing medication or other treatment. Always speak with your physician or other healthcare professional before making any changes to your current regimen.  Information provided in this podcast and the use of any products or services related to this podcast does not create a client-patient relationship between you and the host of Midlife Conversations or you and any doctor or provider interviewed and featured on this show. Information and statements may have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent ANY disease. Advertising Disclosure: Some episodes of Midlife Conversations may be sponsored by products or services discussed during the show. The host may receive compensation for such advertisements or if you purchase products through affiliate links. Opinions expressed about products or services are those of the host and/or guests and do not necessarily reflect the views of any sponsor. Sponsorship does not imply endorsement of any product or service by healthcare professionals featured on this podcast.

In this inspiring episode of Philanthropy in Phocus, Tommy D – the Nonprofit Sector Connector – sits down with his longtime friend Dr. Joy DeDonato, Executive Director for the Metro New York region of Blood Cancer United (formerly the Leukemia & Lymphoma Society). Joy shares how a lifetime of service began with a simple feeling of wanting to help others, and evolved into more than two decades in the nonprofit sector focused on cancer support, education access, women's issues, and amplifying the voices of those who are too often unseen or unheard. She reflects on the powerful example set by her parents, who modeled service “before it had a title,” and how that foundation of love, grit, and doing the right thing has shaped her entire journey.Joy walks listeners through her professional path from Nassau Community College—first as a student, then staff member and later Executive Director of the college's foundation—to a decade at the American Cancer Society, and on to SUNY Stony Brook working on women's health and women's leadership. Throughout, she emphasizes the power of long-term relationships, showing how mentors, colleagues, and friends have stayed connected across roles, institutions, and life milestones. Joy also shares deeply personal stories of losing loved ones to cancer early in her career, and then, 20 years later, watching close family members with blood cancers move from “despair to hope to strength” thanks to advances in treatment—an evolution that called her back into the cancer space and ultimately to Blood Cancer United.Together, Tommy and Joy highlight the recent rebrand from Leukemia & Lymphoma Society to Blood Cancer United, designed to be more inclusive of all blood cancer patients and families. Joy outlines key initiatives including the Dare to Dream project for safer pediatric treatments, the Student Visionaries of the Year campaign, the emotional Light the Night walks, the Big Climb at Citi Field, and the Visionary of the Year competition that rallies leaders to raise critical funds. She also touches on her wider civic leadership as Vice Chair of Dress for Success Long Island and as a commissioner for both Human Rights and Women's Leadership in Suffolk County. Through humor, Golden Girls and Fraggle Rock references, and real talk about grit and service, this episode celebrates how one person's commitment to community, equity, and compassion can ripple out to transform countless lives.

In this week's episode, associate editor Dr. James Griffin interviews researchers Dr. John Semple and Dr. Othman Al-Sawaf on their groundbreaking studies on transfusion-related acute lung injury and chronic lymphocytic leukemia treatment. Dr. Semple explored how mitochondrial DNA could act as a first hit in lung injury, while Dr. Al-Sawaf revealed that patient fitness may not significantly impact the efficacy of targeted CLL treatments. Both studies challenge existing medical assumptions and suggest new approaches to understanding disease mechanisms and treatment responses.Featured ArticlesThe impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLLMitochondrial DNA via recipient TLR9 acts as a potent first-hit in murine transfusion-related acute lung injury (TRALI)

Morning Prayer (people with skin diseases, people with leukemia) #prayer #morningprayer #pray #jesus #god #holyspirit #aimingforjesus #healing #peace #love #bible #skindisease #skincancer #acne #leukemia #remission #family #strength #restThank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peace aimingforjesus.com YouTube Channel https://www.youtube.com/@aimingforjesus5346 Instagram https://www.instagram.com/aiming_for_jesus/ Threads https://www.threads.com/@aiming_for_jesus X https://x.com/AimingForJesus Tik Tok https://www.tiktok.com/@aiming.for.jesus

In this week's episode, Blood editor Dr. Laura Michaelis interviews author Dr. Taylor Brooks on his latest paper published in volume 146 issue 18 of Blood Journal. The conversation discusses outcomes of bispecific antibodies (epcoritamab or glofitamab) in treating aggressive B-cell lymphoma in a study with 245 patients. Findings show a tentative way forward in treatment for patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).Featured Article:Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab

Diagnosed with cancer at 16, Emily hadn't dared hope she would graduate from high school or college, let alone fall in love and get engaged.  

Watch Delta's heartwarming reunion with her dad at St. Jude go viral, capturing the hearts of millions as she battles leukemia.

The former St. Jude patient treated for cancer and sickle cell disease says her health journey helped her become determined, strong and hopeful.

There are calls for greater transparency about how Pharmac prioritises medicines on what is effectively a wait list for funding as it considers culling that list. If the proposal goes ahead the government drug buying agency will focus on cutting drugs that have been in the lowest ranked group on the options for funding list for more than two years. Publicly drugs on the funding wait list appear in alphabetical order; but where they are ranked in terms of priority for funding is kept secret. Leukemia and Blood Cancer chief executive Tim Edmonds spoke to Lisa Owen.

Dr. Hiroto Inaba was raised in a rural province in Japan to honor his samurai heritage. His parents taught him the “Bushido” that an honorable life is one that upholds “the good fight,” Inaba says. After he lost his mother to cancer, he decided his fight would be as an oncologist tackling cancer.

Trick-or-treaters Leave Their Halloween Candy For Child Battling LeukemiaA search for hope at the end of this very anxious week led me to this humble bundle.  Zoe, 3, is the proud product of TJ and Courtney Thomas of Atlanta, Georgia.Back in February, Zoe was diagnosed with leukemia. And because her immune system is now compromised, she couldn't go trick-or-treating on Halloween with all the other kids. In fact, her parents even had to put up a sign to keep other kids away. The sign read: "Sorry, no candy. Child with cancer. See you next year!""The whole purpose was just so that we wouldn't have to keep telling kids 'sorry' and have disappointed kids," Zoe's mother Courtney Thomas said. "Never expected anything like this."How to connect with AgileDad:- [website] https://www.agiledad.com/- [instagram] https://www.instagram.com/agile_coach/- [facebook] https://www.facebook.com/RealAgileDad/- [Linkedin] https://www.linkedin.com/in/leehenson/

In this Review Series episode, Associate Editor Dr. Philippe Armand speaks with multiple authors about what it might look like to improve treatments follicular lymphoma, a disease that has been put on the backburner of innovation due to its generally treatable nature. Dr. Armand discusses "Treatment of relapsed and refractory follicular lymphoma: which treatment for which patient for which line of therapy?" with author Dr. Carla Casulo,  "The future of follicular lymphoma management: strategies on the horizon” with author Dr. Sarah C. Rutherford, and "An updated understanding of follicular lymphoma transformation” with Dr. Erin M. Parry.Find the whole review series on follicular lymphoma in volume 146 issue 15 of Blood Journal.  

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Acute Myelogenous Leukemia (AML)⁠⁠⁠⁠⁠ from the Oncology section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

Leukemia Awareness Month with guest Dr. Nikolai Podoltsev September 28, 2025 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

How do childhood experiences or cultural norms shape a woman's relationship with money?How can someone start rewriting their money story, especially if they feel stuck or ashamed? My guest, Michelle Taylor, has those answers and more for us today.At age 17, she overcame the adversity of Leukemia and launched her business at 27.Michelle shares how that life-changing experience shaped her approach to financial resilience and entrepreneurship.She has dedicated her career to helping women break through limiting beliefs about money, build lasting financial security, and finally feel in control.Through The Women Wealth Initiative, she offers more than advice; she offers a system, a strategy, and a supportive community to help you unlock your full financial potential.Michelle holds a Bachelor's in Business Administration and Marketing, and has been nationally recognized as a leader in financial planning. CONNECT WITH MICHELLE:Instagram - https://www.instagram.com/women_in_wealth/?hl=enLinkedIn - https://www.linkedin.com/in/michelle-taylor-9b396139CONNECT WITH DEBIDo you feel stuck?  Do you sense it's time for a change, but are unsure where to start or how to move forward? Schedule a clarity call!Free Clarity Call: https://calendly.com/debironca/free-clarity-callWebsite – https://www.debironca.comInstagram - @debironcaEmail – info@debironca.com Check out my online course!Your Story's Changing, Finding Purpose in Life's Transitionshttps://course.sequoiatransitioncoaching.com/8-week-programThe Family Letter by Debi Ronca – International Best Sellerhttps://www.amazon.com/dp/B07SSJFXBD

Lurie Children's Hospital has received $4 million from pediatric cancer foundation Cal's Angels to establish the Cal's Angels Advanced Leukemia Clinical and Research Program.

Lurie Children's Hospital has received $4 million from pediatric cancer foundation Cal's Angels to establish the Cal's Angels Advanced Leukemia Clinical and Research Program.

Lurie Children's Hospital has received $4 million from pediatric cancer foundation Cal's Angels to establish the Cal's Angels Advanced Leukemia Clinical and Research Program.

In this week's episode of the Blood Podcast, Associate Editor Dr. James Griffin interviews Drs. Binod Dhakal and Ruben Bierings about their respective papers published in this week's issue of Blood. Dr. Dhakal presents his study on using talquetamab, a bispecific antibody, as a bridging therapy before BCMA-targeted CAR T-cell therapy in multiple myeloma patients, showing promising results with high response rates and manageable toxicities. Next, Dr. Bierings identified patients with genetic variants in the guanine exchange factor MAP kinase–activating death domain (MADD) that impair VWF secretion from endothelial cells and possibly cause VWD type 1. Featured ArticlesA novel cause of type 1 von Willebrand disease: impaired exocytosis of Weibel-Palade bodies due to biallelic MADD variantsSophie Hordijk, Stijn A. Groten, Petra E. Bürgisser, Sebastiaan N. J. Laan, Georg Christoph Korenke, Tomáš Honzík, Diane Beysen, Frank W. G. Leebeek, Paul A. Skehel, Maartje van den Biggelaar, Tom Carter, Ruben BieringsSequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapyBinod Dhakal, Othman S. Akhtar, David Fandrei, Alexandria Jensen, Rahul Banerjee, Darren Pan, Shambavi Richard, Reed Friend, Matthew Rees, Patrick Costello, Mariola Vazquez Martinez, Oren Pasvolsky, Charlotte Wagner, James A. Davis, Omar Castaneda Puglianini, Ran Reshef, Aimaz Afrough, Danai Dima, Manisha Bhutani, Omar Nadeem, Ricardo Parrondo, Ciara Freeman, Lekha Mikkilineni, Shahzad Raza, Larry D. Anderson Jr, Prashant Kapoor, Hitomi Hosoya, Saurabh Chhabra, Ariel Grajales-Cruz, Mahmoud Gaballa, Shonali Midha, Melissa Alsina, Douglas Sborov, Krina Patel, Yi Lin, Christopher Ferreri, Nico Gagelmann, Anupama Kumar, Doris Hansen, Andrew Cowan, Luciano J. Costa, Maximilian Merz, Surbhi Sidana

In this Spotlight series episode on Acute Myeloid Leukemia, Blood Editor, Dr. Selina Luger interviews Drs. Laura Michaelis and Alexander Perl on their paper in the series titled “The fit older adult with acute myeloid leukemia: clinical challenges to providing evidence-based frontline treatment”. The conversation explores challenges in treating AML across different patient populations. They also focus on treatment approaches for fit older adults with AML, highlighting the need for less toxic therapies and ongoing randomized trials to better understand treatment efficacy. See the full spotlight series on Acute Myeloid Leukemia in Volume 145 Issue 24 of Blood journal. 

In this week's episode we'll learn more about a study comparing busulfan-melphalan with melphalan alone as the conditioning protocol for newly diagnosed, transplant-eligible multiple myeloma; then we will discuss data on how three-dimensional transcriptomics can reveal complex interactions between plasma cells and bone marrow microenvironments.Featured ArticlesHigh-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trialProfiling the spatial architecture of multiple myeloma in human bone marrow trephine biopsy specimens with spatial transcriptomicsPreclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma

In this episode of I Am Refocused Radio, host Shemaiah Reed sits down with entrepreneur and commercial real estate powerhouse Chuck Cuda, founder of OPES Commercial Real Estate and CEO of Elevation Cannabis.As CEO of Elevation Cannabis, he expanded operations from five to 22 licenses across three states, proving his ability to grow and disrupt industries.But Chuck's success doesn't stop at business. In 2018, he founded the OPES Charitable Foundation, which has raised more than $3 million for causes like cancer research and autism awareness. He also serves on local boards — including the Leukemia and Lymphoma Society — and mentors young athletes through youth baseball, helping shape the next generation of leaders.This conversation dives deep into leadership, innovation, giving back, and what it really takes to build something that lasts.Become a supporter of this podcast: https://www.spreaker.com/podcast/i-am-refocused-radio--2671113/support.Thank you for tuning in to I Am Refocused Radio. For more inspiring conversations, visit IAmRefocusedRadio.com and stay connected with our community.Don't miss new episodes—subscribe now at YouTube.com/@RefocusedRadio

The government just announced a warning label will be added to Tylenol that use during pregnancy may be associated with an increased risk of Autism and ADHD in children..  In this episode, we talk about:—How the makers of Tylenol admitted in their own  internal documents that there is a strong correlation between Tylenol and Autism. —Why Tylenol's interference with the Liver's capability of making Glutathione is the mechanism  behind Tylenol contributing to neurological issues.  And how a rash on babies after giving them Tylenol after vaccination can be a signal that something has gone wrong with the Liver.—The reason Dr. Prather says that Tylenol causes damage to the Kidneys, Liver, and Gut every time you take it.  And the long list of potential harm that Tylenol can cause, including:  Liver damage, Kidney damage, G.I. bleeding, Diarrhea, Vomiting, Heart failure, Heart attacks, Hypertension, Undescended testicles, Asthma, and an increased chance of Cancers like Leukemia. —The benefits of Fever to the body and why Dr. Prather says there is "a tremendous amount of really good things that happen with a Fever."  And why the approach to just suppress a Fever leads to more problems and worse results.—How Fever is an indication of a Neurology issue and can actually reveal a lot of helpful diagnostic information.  And how Chiropractic is the way to deal with Neurological situations, including Fevers.—The chances of seizures from a Fever are not decreased by Tylenol, but Structure-Function Care can help the body avoid seizures by keeping the body in Homeostasis.  And how Tylenol is not only dangerous, but research shows it also has very little effectiveness for pain. —The Spleen-21 Acupuncture point that Dr. Prather's staff immediately request treatment on when they start to feel sick.  And the "really excellent" Elderberry and Vitamin C syrup that is very easy for children to take when they are ill.—Why Dr. Prather says that Homeopathy is "extremely effective for children" and is always safe.  And how it is "the best and safest way to help a child's immune system work better".—The Diathermy treatment Dr. Prather uses in his office to bring immediate relief to crying children with ear infections and "usually clears up the ear discomfort in one session".  And the gentle Galbreath maneuver Dr. Prather teaches Moms to do on their babies to promote ear drainage. —How Dr. Prather says that Autism can be reversed and how he has seen "really strong changes in Autism and ADHD".  And the methods that Holistic Integration uses, such as Craniosacral Therapy, to reverse the damage from the toxicities that cause Autism.http://www.TheVoiceOfHealthRadio.com

Today, I'm joined by the remarkable Dr. Lisa Koche, a leukemia survivor turned clinician who has spent her career bridging the worlds of conventional, functional, and quantum medicine. In our conversation, Dr. Koche opens up about her unique journey—from facing a life-altering cancer diagnosis at just fifteen, to questioning conventional medical dogma, to becoming a pioneer in mitochondrial health, personalized medicine, and nervous system regulation.   Episode Timestamps: Leukemia diagnosis and integrative healing journey ... 00:04:00 From patient to physician: asking “why” in medicine ... 00:07:00 Building collaborative, personalized care ... 00:11:00 Biohacking, mitochondria, and the limits of one-size-fits-all ...00:13:00 Wearables, nervous system, and self-assessment ... 00:18:00 Quantum biology, intuition, and energetic health ... 00:23:00 Supplements, subtle energy modalities, and future trends ... 00:32:00 Regenerative and mitochondrial testing advances ... 00:34:00 Nervous system regulation and the risk of overdoing biohacks ... 00:41:00 Guiding patients: self-awareness, nature, and media boundaries ... 00:44:00 Food, minerals, intention, and foundational self-care ... 00:55:00 Bridging science, energy, and personal sovereignty ... 01:00:00 A paradigm-shifting energy healing experience ... 01:02:00   Our Amazing Sponsors: Digestive Bitters by Just Thrive - One capsule before eating helps your body absorb more nutrients, ease digestion, and leave you feeling light instead of weighed down. Head over to Justthrivehealth.com/discount/NAT and use code NAT20 for 20% off.   NootroPept by LVLUP - an advanced cognitive enhancement formula that combines fast-acting neuropeptides, cholinergic support, and mitochondrial-boosting compounds to sharpen mental clarity, memory, and long-term brain performance. Visit https://lvluphealth.com/ and use code NAT at checkout for 20% off.    NMN+G Rx by Wizard Sciences - A scientifically formulated blend of NMN, ginsenosides from Panax ginseng, and apigenin. Together, they enhance mitochondrial function, boost NAD+ levels, and support cellular repair. Go to wizardsciences.com and look for NMN+G. Use code NAT15 at checkout to get 15% off your purchase.   Nat's Links:  YouTube Channel Join My Membership Community Sign up for My Newsletter  Instagram  Facebook Group

Dana Mooney, a mother of a 17-year-old autistic son, Preston, who has leukemia, stopped his chemotherapy treatment after eight months due to his declining health. She sought alternative treatments, finding a doctor who offered a plan based on genetic testing, which revealed a mutation preventing chemo absorption. Despite Preston's improvement on the alternative treatment, a referral was made against Dana, accusing her of mistreatment, and Preston was placed in state custody, requiring him to resume chemotherapy.   A mother was pressured by DHS and a caseworker to admit her autistic son to OU Children's Hospital, despite her concerns about the treatment plan and the hospital's financial incentives. The mother felt intimidated and coerced into signing paperwork, fearing separation from her son. The situation highlights the concerning power dynamics between state agencies, hospitals, and parents in medical decision-making.   Preston, a 17-year-old with autism, was taken into state custody after a caseworker, with a signed court order, tricked his mother, Dana, into handing him over. Despite Dana's objections and Preston's own wishes, the state administered chemotherapy and a blood transfusion, disregarding his preference for alternative medicine. The situation raises concerns about the lack of transparency and the power dynamics involved in such decisions.   Roberta Lewis observed a DHS-contracted sitter, hired through the company Synergy, who was unaware of the family's situation and only there to “sit.” The sitter's role was to observe the family, creating an intimidating environment and hindering open communication. Lewis questioned the purpose of these sitters, noting their lack of training, reporting responsibilities, and the potential misuse of taxpayer funds.   The state of Oklahoma is currently footing the bill for medical treatment for Preston, a child in DHS custody. This situation highlights the violation of parental authority and bodily autonomy, as well as the need for transparency in the court system and a new model for the DHS. The case is gaining national attention and may be the catalyst for change in the system.   Check out my sponsors!  Motus Health motushealth.com Stevens Trucking stevenstrucking.com  

Mom Curious is a weekly podcast produced by Hoff Studios in New York City, hosted by storyteller, actress, and thought leader Daniella Rabbani. Each episode dives into candid conversations about motherhood, womanhood, and the messy, magical spaces in between. With humor, honesty, and (you guessed it!) curiosity, Daniella sits down with women of all stripes to talk about what it really means to raise children—and ourselves—in today's world.About the Host:Daniella Rabbani (@DaniellaRabbani on Instagram) is a Brooklyn-based storyteller. On screen, she's appeared in HBO's Scenes from a Marriage, Amazon's The Better Sister, FX's The Americans, and films like Ocean's 8. On stage, she's headlined concerts worldwide, from Jazz at Lincoln Center in NYC to the State Jewish Theaters of Warsaw, Poland and Bucharest, Romania. She is also the voice behind national campaigns for Colgate, Starbucks, and Noom among others. Her award winning film OMA, inspired by her Holocaust survivor grandmother, can be seen on Amazon Prime.Through her podcast Mom Curious, Daniella blends her creative spirit and lived experience as a mother of two to spark conversations that are raw, hilarious, and deeply relatable. Her mission: to create a community where mothers (and those curious about motherhood) feel seen, supported, and inspired.This Week's Guest!Caitlin Murray is a humorist, content creator, writer, podcaster, mother of three and wife of one. She is the creator of Big Time Adulting. In 2016, Caitlin's oldest child was diagnosed with Leukemia at age three. Caitlin began sharing with family and friends about their journey and, specifically, her experience as a mother. Caitlin started her Instagram account in 2018 and has amassed over a million followers who appreciate her for her honest and humorous takes on motherhood. Her book comes out in 2026! Follow Caitlin at @bigtimeadulting on Instagram. Learn more about your ad choices. Visit megaphone.fm/adchoices

Help us end childhood Cancer here: https://fundraising.stjude.org/site/TR/Heroes/SJMMW?px=5816464&pg=personal&fr_id=158671©_link_share Ministry Spotlight: Partners 4 Africa- http://partners4africa.com/ Healing Hands International is a proud sponsor of this podcast. Get more info about them here: https://www.hhi.org/ Will shares info about our ministry spotlight on "Partners 4 Africa". Ben and Travis then discuss Travis' leukemia battle and practical ways to stay encouraged while facing trials and scary moments. The episode wraps up with the Healing Hands International Question of the Day. Links mentioned in this episode: Get our free ebook "28 Days of Focused Living" here: https://www.benandtravis.com https://www.facebook.com/groups/benandtravis Reframing Hope Book: https://www.benandtravis.com/books For extra content and material you can use for your family or ministry go to https://www.patreon.com/benandtravis Represent the show: https://www.benandtravis.com/store The Friday ReFresh: https://podcasts.apple.com/us/podcast/the-friday-refresh/id1611969995 Good Old Fashioned Dislike Podcast: https://podcasts.apple.com/us/podcast/good-old-fashioned-dislike/id1643163790 Co-Producers: Justin B., Doris C., Rhonda F., Scott K., Mary H., Scott B. This podcast is hosted by ZenCast.fm

On this now two year anniversary, I felt that this deserved a replay! This is an episode that is an enormous part of why I've changed the brand of the podcast to encompass the broader human experience. My daughter, Jocelyn, is my very special guest today. She talks about her leukemia diagnosis over two years ago, and the battle that would take up all of 2023, and change the way she has to look at her health for the rest of her life. Hearing this story from her provides so much joy for who she is as a woman, how she's grown, and my hope is that you'll hear the same message.  She shares some of the early indicators that were thought to be a bad case of the flu, the mysterious bruises she got, and when she checked in to Phoenix Children's Hospital. She talks about shaving her head, the incredible people that stepped up for her when she was down, and the quirky things that people say and do - when they don't know what to say or do! The lesson and ongoing message in this podcast for all of us is, I believe, that through struggle and adversity comes strength. I'm so proud of my daughter - and the lessons I believe are important for anyone struggling.  I hope that you find this episode to be uplifting and motivating for your own human experience. Thank you so much for listening! Stacie More episodes at StacieBaird.com.

This episode of WNY Brews is brought to you by The Tap and Craft Festival at Buffalo Riverworks on October 4th, presented by The Lock Tender. Ticket information is available now at BuffaloBeerLeague.com/tapandcraft.This week, we've got a lot to raise a glass to. Hofbrauhaus Buffalo is celebrating five years with a big Bavarian bash, and Southern Tier Buffalo is hosting Pumkingfest with all the seasonal favorites and variants you could want. Wayland Brewing is throwing their third annual Oktoberfest weekend with music, food, steins and even axe throwing, while Buffalo Riverworks is gearing up for the Tap & Craft Festival with a stacked brewery list. Resurgence brings back the Dude's Homebrew Competition in support of the Leukemia & Lymphoma Society, Big Ditch is taking over taps at Nickel City Cigars, and Fattey Beer Co. just opened a new Amherst location. Plus, Bev Depot is hosting a fall tasting with samples from Mortalis, Big Ditch, Thin Man, and more.You can find all of these stories and more at BuffaloBeerLeague.com.WNY Brews is hosted by Scott Panfil and Brian Campbell. Reach us anytime at Brian@BuffaloBeerLeague.com and Scott@WNYBrews.com. Hosted on Acast. See acast.com/privacy for more information.

Dr. Lachelle Weeks is a physician-scientist at Dana-Farber Cancer Institute working on a project to predict leukemia risk based on widely available blood samples.